Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
佛罗里达州坦帕，2024年7月23日（GLOBE NEWSWIRE）——帕西拉生物科学公司（纳斯达克股票代码：PCRX）今天宣布，它将在2024年7月30日星期二美国市场收盘后公布其第二季度财务业绩。发布后，该公司将在美国东部时间下午 4:30 举办电话会议和网络直播。
For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.
对于希望通过电话参加问答环节的听众，请在此处预注册。所有注册者都将收到拨入信息和PIN，允许他们访问实时通话。此外，电话会议的现场音频将以网络直播的形式提供。有兴趣的人士可以通过帕西拉网站investor.pacira.com上的 “活动” 页面访问该活动。对于那些无法参与直播的人，电话会议结束后的大约两周内将在Pacira网站上重播网络直播。
About Pacira
关于 Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioverao, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit .
Pacira BioSciences, Inc.（纳斯达克股票代码：PCRX）致力于为尽可能多的患者提供非阿片类药物选择，以重新定义阿片类药物仅作为救援疗法的作用。该公司还在开发创新的干预措施，以解决涉及交感神经系统的衰弱性疾病，例如心脏电暴、慢性疼痛和痉挛。帕西拉有三种商业阶段的非阿片类药物疗法：EXPAREL（布比卡因脂质体注射混悬液），一种长效局部镇痛药，目前获准用于术后疼痛管理；ZILRETTA（曲安奈德丙酮缓释注射悬浮液），一种用于治疗骨关节炎膝盖疼痛的缓释关节内注射剂；以及ioverao，一种新型的手持式设备使用精确、可控的低温剂量对目标神经进行即时、长效、无药物的疼痛控制。要了解有关Pacira的更多信息，包括减少对阿片类药物的过度依赖的企业使命，请访问。
CONTACT: Investor Contact:
Pacira BioSciences, Inc.
Christian Pedetti, (973) 254-4387
Christian.Pedetti@pacira.com
联系人：投资者联系人：
Pacira Biosciences, Inc
克里斯蒂安·佩德蒂，(973) 254-4387
Christian.Pedetti@pacira.com